Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 18/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 4/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770357 | 1.00 | MCL1 (0.52) | MCL1P2RX3BCL2BCL2L1MMP2 | |
| SCHEMBL25365111 | 0.90 | P2RX3 (0.53) | MCL1P2RX3BCL2BCL2L1 | |
| SCHEMBL6846804 | 0.90 | P2RX3 (0.53) | MCL1P2RX3 | |
| SCHEMBL6846802 | 0.90 | P2RX3 (0.53) | MCL1P2RX3 | |
| SCHEMBL18617461 | 0.89 | P2RX3 (0.52) | MCL1P2RX3 | |
| SCHEMBL12442648 | 0.89 | P2RX3 (0.52) | MCL1P2RX3 | |
| SCHEMBL3263994 | 0.89 | P2RX3 (0.63) | MCL1P2RX3BCL2BCL2L1MMP2 | |
| SCHEMBL18754654 | 0.89 | P2RX3 (0.52) | MCL1P2RX3 | |
| SCHEMBL29523156 | 0.89 | P2RX3 (0.52) | MCL1P2RX3 | |
| SCHEMBL15719188 | 0.88 | P2RX3 (0.51) | MCL1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | MCL1 1583/4885P2RX3 1304/4885BCL2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.